HomeCompareFREQ vs ADC

FREQ vs ADC: Dividend Comparison 2026

FREQ yields 667.56% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FREQ wins by $614801.88M in total portfolio value
10 years
FREQ
FREQ
● Live price
667.56%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$614802.06M
Annual income
$474,868,230,549.69
Full FREQ calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — FREQ vs ADC

📍 FREQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFREQADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FREQ + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FREQ pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FREQ
Annual income on $10K today (after 15% tax)
$56,742.32/yr
After 10yr DRIP, annual income (after tax)
$403,637,995,967.24/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, FREQ beats the other by $403,637,927,289.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FREQ + ADC for your $10,000?

FREQ: 50%ADC: 50%
100% ADC50/50100% FREQ
Portfolio after 10yr
$307401.12M
Annual income
$237,434,155,673.50/yr
Blended yield
77.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

FREQ
Analyst Ratings
3
Buy
4
Hold
Consensus: Hold
Price Target
$1.40
+367.3% upside vs current
Range: $1.40 — $1.40
Altman Z
-7.4
Piotroski
3/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FREQ buys
0
ADC buys
0
No recent congressional trades found for FREQ or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFREQADC
Forward yield667.56%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$614802.06M$178.9K
Annual income after 10y$474,868,230,549.69$80,797.29
Total dividends collected$603369.48M$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$1.40$81.06

Year-by-year: FREQ vs ADC ($10,000, DRIP)

YearFREQ PortfolioFREQ Income/yrADC PortfolioADC Income/yrGap
1← crossover$77,456$66,755.67$10,990$580.36+$66.5KFREQ
2$566,112$483,234.18$12,301$860.26+$553.8KFREQ
3$3,906,567$3,300,827.31$14,104$1,298.62+$3.89MFREQ
4$25,467,892$21,287,865.51$16,691$2,008.16+$25.45MFREQ
5$156,952,466$129,701,821.96$20,580$3,205.09+$156.93MFREQ
6$914,968,107$747,028,968.25$26,754$5,330.02+$914.94MFREQ
7$5,048,988,394$4,069,972,519.36$37,196$9,345.14+$5048.95MFREQ
8$26,392,111,970$20,989,694,387.90$56,244$17,523.09+$26392.06MFREQ
9$130,779,275,796$102,539,715,988.68$94,286$35,736.21+$130779.18MFREQ
10$614,802,055,652$474,868,230,549.69$178,949$80,797.29+$614801.88MFREQ

FREQ vs ADC: Complete Analysis 2026

FREQStock

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Full FREQ Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this FREQ vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FREQ vs SCHDFREQ vs JEPIFREQ vs OFREQ vs KOFREQ vs MAINFREQ vs NNNFREQ vs EPRTFREQ vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.